Anika Therapeutics Inc. $ANIK Stock Position Reduced by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its stake in Anika Therapeutics Inc. (NASDAQ:ANIK) by 24.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,984 shares of the biotechnology company’s stock after selling 16,701 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.36% of Anika Therapeutics worth $781,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ANIK. Acadian Asset Management LLC increased its stake in shares of Anika Therapeutics by 13.4% in the first quarter. Acadian Asset Management LLC now owns 539,614 shares of the biotechnology company’s stock worth $8,107,000 after acquiring an additional 63,901 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Anika Therapeutics by 81.3% in the fourth quarter. Ameriprise Financial Inc. now owns 46,093 shares of the biotechnology company’s stock valued at $759,000 after purchasing an additional 20,663 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Anika Therapeutics by 408.6% in the fourth quarter. BNP Paribas Financial Markets now owns 14,448 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 11,607 shares in the last quarter. Wellington Management Group LLP increased its position in Anika Therapeutics by 3.7% in the 4th quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 1,407 shares during the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in shares of Anika Therapeutics during the 4th quarter worth about $231,000. Institutional investors and hedge funds own 91.53% of the company’s stock.

Anika Therapeutics Stock Performance

Shares of ANIK opened at $9.12 on Wednesday. The company has a 50-day simple moving average of $9.27 and a 200-day simple moving average of $11.70. Anika Therapeutics Inc. has a 52 week low of $7.87 and a 52 week high of $25.65. The firm has a market capitalization of $131.49 million, a P/E ratio of -2.20 and a beta of 0.63.

Analyst Ratings Changes

Separately, Barrington Research reissued an “outperform” rating and issued a $15.00 price target on shares of Anika Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and an average price target of $18.00.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.